KRAS and colorectal carcinoma: Consequently, KRAS mutation status is a crucial biomarker for guiding treatment decisions, as the presence of these mutations predicts a lack of response to cetuximab and panitumumab, two commonly used monoclonal antibodies in the management of metastatic CRC [9,10].